Drug Trial Radar · NCT02973672
Phase I of SGM-101 in Patients With Cancer of the Colon, Rectum or Pancreas
Last checked: Nov 19, 2026Latest source record: Jul 18, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
75
Actual
Start
Jan 2016
Primary completion
Apr 15, 2019
Study completion May 2019
Sponsor
- Lead sponsor
- SurgimabIndustry
- Sponsor type
- Industry
- Collaborators
- Centre for Human Drug Research, Netherlands; Leiden University Medical Center; Erasmus Medical Center; Catharina Ziekenhuis Eindhoven
- First posted
- Nov 25, 2016
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study evaluates the safety and performance of SGM-101, a Carcinoembryonic Antigen (CEA)-specific chimeric antibody conjugated with a NIR emitting fluorochrome, for the visualization of CEA-expressing cancers during surgery. SGM-101 is injected 2 to 4 days before surgery and visualized using an optimized camera system.
Conditions
- Colon Cancer
- Rectum Cancer
- Pancreas Cancer
- Metastatic Colorectal Cancer
- Recurrent Colorectal Carcinoma
Interventions
SGM-101Drug
4 days before surgery, SGM-101 will be administered to the patient by intravenous injections.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of patients with treatment-related adverse eventsTime frame: up to 10 days after the surgery
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Catharina Ziekenhuis Eindhoven
Eindhoven, Netherlands
Leiden University Medical Center
Leiden, Netherlands
Erasmus Medical Center Cancer Institute
Rotterdam, Netherlands
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.